Physician profile
Charbel E Aoun
NPI 1023121217
$3,372.52
in general payments reported to CMS, 2019-2025
18 companies · $46.90 in 2025
The $46.90 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $35.01 · 2021: $358 · 2022: $2,426 · 2023: $301 · 2024: $98.31 · 2025: $46.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.78 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $2,008.81 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $419.87 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $239.95 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $124.93 | 2019-2023 | Mounjaro |
| Pfizer INC. | $113.47 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $83.75 | 2019-2021 | |
| Novo Nordisk INC | $64.91 | 2023-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $61.11 | 2022-2023 | Eliquis |
| Abbott Laboratories | $51.59 | 2021-2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $42.27 | 2019-2025 | Shingrix |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.79 | 2019-2020 | |
| Dexcom, INC. | $23.70 | 2021 | |
| Boston Scientific Corporation | $23.56 | 2024 | Wavewriter Alpha Prime 16 |
| Sanofi Pasteur INC. | $21.89 | 2023 | |
| Avanir Pharmaceuticals, INC. | $21.24 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.97 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charbel Aoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.